View all the latest information in myelodysplastic syndromes, arranged by therapeutic class and intervention. Listed below are recently updated therapeutic classes.
Results from the phase II P-2001 study on pevonedistat plus azacytidine for high-risk MDS
To further explore the clinical efficacy and safety of pevo in patients with high-risk MDS, CMML, or low-blast...
P-2001 study: Which patients benefit most from pevonedistat plus azacitidine?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Mikkael Sekeres,...
Should the telomerase inhibitor imetelstat become SoC in transfusion-dependent low-risk MDS?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to...
Imetelstat for patients with highly transfusion-dependent MDS
The initial treatment option for patients with lower-risk MDS is the use of erythropoiesis-stimulating agents (ESAs) with/without other...
Eprenetapopt with azacytidine did not significantly improve CR rates in TP53-mutated MDS
Phase III trial of eprenetapopt (APR-246) with azacytidine had not met its primary endpoint: the CR rates in...
Targeted therapeutics in MDS – what’s the current state of play?
During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the MDS Hub podcast channel spoke to Dr David Sallman,...
RIC allo-SCT vs HMA or best supportive care in older patients with high-risk MDS
The BMT CTN designed the phase II randomized trial 1102 (NCT02016781), to assess the benefits of reduced intensity...
When should we consider allo-SCT for patients with MDS?
Corey Cutler talks about the results from the Blood and Marrow Transplant Clinical Trials Network study 1102.
Cytokine receptor agonists
TGF-β pathway inhibitors